Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06549504

Bioequivalence Study of AG2202

An Open-label, Randomized, Fasting, Single, Oral Administration, Group 2, Stage 2, Cross-over Bioequivalence Study of AG2202 in Healthy Volunteers

Status
Not Yet Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
34 (estimated)
Sponsor
Ahn-Gook Pharmaceuticals Co.,Ltd · Industry
Sex
All
Age
19 Years
Healthy volunteers
Accepted

Summary

The objective of this study is to evaluate the human bioequivalence of AG2202T and AG2202R.

Detailed description

To evaluate the bioequivalence of two formulations of AG2202T and AG2202R after a single oral dose administration in healthy Korean subjects under fasting conditions.

Conditions

Interventions

TypeNameDescription
DRUGAG2202TAG2202T Single-dose
DRUGAG2202RAG2202R Single-dose

Timeline

Start date
2024-08-01
Primary completion
2024-09-01
Completion
2024-09-01
First posted
2024-08-12
Last updated
2024-08-14

Source: ClinicalTrials.gov record NCT06549504. Inclusion in this directory is not an endorsement.

Bioequivalence Study of AG2202 (NCT06549504) · Clinical Trials Directory